刊物主题:Gynecology; Obstetrics/Perinatology; Endocrinology; Human Genetics;
出版者:Springer Berlin Heidelberg
ISSN:1432-0711
卷排序:295
文摘
ObjectiveNo consensus exists on the number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced stage epithelial ovarian cancer. The present study aims to explore the optimal number of cycles of neoadjuvant chemotherapy (NAC) and post-operation chemotherapy to treat the International Federation of Gynecology and Obstetrics stage IIIc–IV high-grade serous ovarian cancer (HG-SOC).